研究单位：[1]Huazhong University of Science and Technology[2]Department of Hematology Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030[3]Jiangxi The First Afliated Hospital of Nanchang University Nanchang,Jiangxi,China
研究目的：
The is a phase II, single-arm, open-label clinical study assessing the efficacy and safety of Camrelizumab combined with CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 30 subjects with r/r CD30+ lymphoma。
